Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Conference

New data regarding repeat treatments of SIR-Spheres® microspheres in patients with advanced liver tumors to be included at annual meeting

LAKE FOREST, Ill. (March 27, 2007) – Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 43rd Annual American Society of Clinical Oncology (ASCO) conference. The meeting, to be held June 1-5 at the McCormick Place in Chicago, Ill., is considered the premier educational and scientific event in the oncology community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has spread to the liver.¹

In addition to the exhibition, new data regarding repeat treatments of SIR-Spheres microspheres will be included in the program. The paper authored by Andrew Kennedy, M.D., F.A.C.R.O, co-medical director of Wake Radiology Oncology in Cary, N.C., examined safety and patient selection regarding repeat microsphere radioembolization for hepatic malignancies. As patients live longer with hepatic tumors, a growing number of them require retreatment. According to Kennedy, with proper patient selection, repeat radiation to the liver with SIR-Spheres microspheres is safe and no dosing adjustments are needed.

“Sirtex is proud to support ASCO and its mission to improve cancer care and prevention and ensure that all cancer patients receive care of the highest quality,” says Nat Geissel, CEO, Sirtex Medical Inc. “We believe it is imperative that Sirtex continues to participate in meetings such as this to allow physicians the opportunity to learn about the latest advances and research regarding SIR-Spheres microspheres. We are able to speak directly with physicians and provide information that will ultimately help improve the level of care we are able to offer patients with advanced liver disease.”

Sirtex’s SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. According to a paper in the International Journal of Radiation Oncology Biology Physics, the use of SIR-Spheres microspheres in patient responders resulted in a median survival rate of 10.5 months from treatment.
Approximately 90 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 86 medical centers. The minimally invasive procedure is performed on an outpatient basis with minor side effects.

1 Sirtex Medical Inc.’s SIR-Spheres® microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer reviewed literature is different from the approved USA labeling for SIR-Spheres.

About Sirtex
SIR-Spheres microspheres were developed in the 1980s in Australia and were approved by the FDA in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit www.sirtex.com.

® SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

###